Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel Free AVTE Stock Alerts

Aerovate Therapeutics (AVTE) Competitors

Aerovate Therapeutics logo
$14.12 +0.35 (+2.54%)
As of 10/2/2026
Compare

AVTE vs. NBTX, STOK, ABSI, TSHA, and NTLA

Should you buy Aerovate Therapeutics stock or one of its competitors? Aerovate Therapeutics's main competitors and comparable companies include Nanobiotix (NBTX), Stoke Therapeutics (STOK), Absci (ABSI), Taysha Gene Therapies (TSHA), and Intellia Therapeutics (NTLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aerovate Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

38.8% of Nanobiotix shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nanobiotix currently has a consensus target price of $46.67, suggesting a potential upside of 81.23%. Given Nanobiotix's stronger consensus rating and higher possible upside, research analysts plainly believe Nanobiotix is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanobiotix
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Nanobiotix has higher revenue and earnings than Aerovate Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nanobiotix$36.87M35.35-$27.11MN/AN/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

Nanobiotix has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NanobiotixN/A N/A N/A
Aerovate Therapeutics N/A -90.19%-77.47%

In the previous week, Nanobiotix had 10 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 10 mentions for Nanobiotix and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat Nanobiotix's score of -0.20 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Nanobiotix Neutral
Aerovate Therapeutics Neutral

Summary

Nanobiotix beats Aerovate Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Stoke Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Stoke Therapeutics has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stoke Therapeutics$27.59M59.92-$6.89M-$3.34N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

Aerovate Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Stoke Therapeutics-753.60% -59.36% -51.46%
Aerovate Therapeutics N/A -90.19%-77.47%

In the previous week, Stoke Therapeutics had 6 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Stoke Therapeutics and 0 mentions for Aerovate Therapeutics. Stoke Therapeutics' average media sentiment score of 0.86 beat Aerovate Therapeutics' score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Stoke Therapeutics Positive
Aerovate Therapeutics Neutral

Stoke Therapeutics currently has a consensus price target of $44.25, suggesting a potential upside of 72.72%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Stoke Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Stoke Therapeutics beats Aerovate Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Absci?

Absci (NASDAQ:ABSI) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Aerovate Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Absci-7,756.38% -61.71% -54.52%
Aerovate Therapeutics N/A -90.19%-77.47%

52.1% of Absci shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aerovate Therapeutics has lower revenue, but higher earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Absci$2.80M678.47-$115.18M-$0.80N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

In the previous week, Absci had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Absci and 0 mentions for Aerovate Therapeutics. Absci's average media sentiment score of 1.25 beat Aerovate Therapeutics' score of 0.00 indicating that Absci is being referred to more favorably in the media.

Company Overall Sentiment
Absci Positive
Aerovate Therapeutics Neutral

Absci presently has a consensus price target of $13.71, suggesting a potential upside of 23.89%. Given Absci's stronger consensus rating and higher probable upside, equities research analysts plainly believe Absci is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Absci
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Absci has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Summary

Absci beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Aerovate Therapeutics has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taysha Gene Therapies$9.77M154.41-$109M-$0.42N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Taysha Gene Therapies and 0 mentions for Aerovate Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.55 beat Aerovate Therapeutics' score of 0.00 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company Overall Sentiment
Taysha Gene Therapies Positive
Aerovate Therapeutics Neutral

Taysha Gene Therapies currently has a consensus target price of $12.77, suggesting a potential upside of 175.79%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Taysha Gene Therapies
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.00
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Taysha Gene Therapies' return on equity of -56.19% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Taysha Gene TherapiesN/A -56.19% -41.84%
Aerovate Therapeutics N/A -90.19%-77.47%

Summary

Taysha Gene Therapies beats Aerovate Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Intellia Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Aerovate Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Intellia Therapeutics -672.16%-57.79%-47.29%

Intellia Therapeutics has a consensus price target of $20.98, indicating a potential upside of 71.11%. Given Intellia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Intellia Therapeutics
4 Sell rating(s)
8 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.35

In the previous week, Intellia Therapeutics had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Intellia Therapeutics and 0 mentions for Aerovate Therapeutics. Intellia Therapeutics' average media sentiment score of 1.84 beat Aerovate Therapeutics' score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Intellia Therapeutics Very Positive

Aerovate Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Intellia Therapeutics$59.51M28.87-$412.69M-$3.36N/A

88.8% of Intellia Therapeutics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Intellia Therapeutics beats Aerovate Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTE vs. The Competition

Export
MetricAerovate TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$409.27M$3.87B$7.14B$13.17B
Dividend YieldN/A3.64%2.53%16.78%
P/E Ratio-4.7213.06275.6826.04
Price / SalesN/A1,394.71662.25102.14
Price / CashN/A122.6077.6051.75
Price / Book3.5716.6310.936.31
Net Income-$75.52M-$22.71M$3.51B$362.16M
7 Day Performance-2.08%-2.99%-2.00%-1.66%
1 Month Performance-34.02%-10.60%-6.15%-4.50%
1 Year Performance69.51%19.44%7.44%2.06%

Aerovate Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTE
Aerovate Therapeutics
N/A$14.12
+2.5%		N/A+51.2%$409.27MN/AN/A20
NBTX
Nanobiotix
2.4475 of 5 stars		$31.50
-3.4%		$46.67
+48.1%		+29.5%$1.65B$36.87MN/A97
STOK
Stoke Therapeutics
3.0734 of 5 stars		$25.88
+1.5%		$44.25
+71.0%		+3.2%$1.65B$27.59MN/A170
ABSI
Absci
2.7115 of 5 stars		$10.14
+6.8%		$13.71
+35.2%		+211.8%$1.63B$2.80MN/A140
TSHA
Taysha Gene Therapies
2.5317 of 5 stars		$4.99
flat		$12.77
+155.9%		-5.1%$1.63B$5.49MN/A99

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AVTE) was last updated on 10/3/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel